# US 12,594,330 B2 · Anti-opioid compounds and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,330 B2
- Document ID: US12594330B2
- Status: Granted
- Kind: B2
- Application number: 17/616,031
- Filed: 2020-06-04
- Published: 2022-09-22
- Granted: 2026-04-07
- Earliest claimed: 2019-06-04
- Assignees: Regents of the University of Minnesota; Hennepin Healthcare Research Institute
- Applicants: Regents of the University of Minnesota; Hennepin Healthcare Research Institute
- Inventors: Marco Pravetoni; Carly Baehr
- Web page: https://patentgrep.com/patent/US12594330B2

## CPC

- A61K 39/39533: {against materials from animals}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure describes opioid-specific monoclonal antibodies (mAb), methods of making those antibodies, and methods of using those antibodies. The methods include, for example, treating a subject with an opioid use disorder or neonatal opioid withdrawal syndrome or preventing and reversing opioid overdose in a subject. Additionally or alternatively, the antibodies may be used to detect opioids including, for example, in a screening, diagnostic, or forensic assay.

## Claims

### Claim 1

A polypeptide comprising:
the amino acid sequence of SEQ ID NO: 101; and
the amino acid sequence of SEQ ID NO:104.

### Claim 2 (depends on 1)

A method comprising administering the polypeptide of claim 1 to a subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject may be exposed to an opioid, is suspected of being exposed to an opioid, or has been exposed to an opioid.

### Claim 4

A polypeptide comprising the amino acid sequence of SEQ ID NO:162.

### Claim 5 (depends on 4)

A method comprising administering the polypeptide of claim 4 to a subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject may be exposed to an opioid, is suspected of being exposed to an opioid, or has been exposed to an opioid.

### Claim 7

An antibody heavy chain comprising the amino acid sequence of SEQ ID NO:162.

### Claim 8 (depends on 7)

The antibody heavy chain of claim 7, wherein the heavy chain is humanized.

### Claim 9 (depends on 8)

A method comprising administering the antibody heavy chain of claim 8 to a subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject may be exposed to an opioid, is suspected of being exposed to an opioid, or has been exposed to an opioid.

### Claim 11 (depends on 7)

A method comprising administering the antibody heavy chain of claim 7 to a subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject may be exposed to an opioid, is suspected of being exposed to an opioid, or has been exposed to an opioid.